» Articles » PMID: 32300145

CREB1 is Affected by the MicroRNAs MiR-22-3p, MiR-26a-5p, MiR-27a-3p, and MiR-221-3p and Correlates with Adverse Clinicopathological Features in Renal Cell Carcinoma

Overview
Journal Sci Rep
Specialty Science
Date 2020 Apr 18
PMID 32300145
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

The transcription factor cAMP response element-binding protein (CREB1) has been shown to be involved in diverse biological pathways including the regulation of cell proliferation, apoptosis, cell cycle progression, and metastasis. In this context, aberrant expression of CREB1 and the functional consequences are well investigated in a number of hematopoietic and solid tumors. However, CREB1 expression and underlying control mechanisms are only poorly analyzed in renal cell carcinoma (RCC). The present study confirmed a deregulation of CREB1 protein in the clear cell type of RCC (ccRCC) and analysis of in-house ccRCC cell lines suggested a post-transcriptional control. The combination of miRNA enrichment assay, in silico analysis and molecular biological approaches revealed four novel CREB1-regulating miRNAs, namely miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p. Categorizing RCC samples as CREB1 negative or positive, respectively, the expression of these miRNAs was found to be inversely correlated with CREB1 protein levels. Analyzing 453 consecutive RCC tumors by immunohistochemistry, weakly negative, but significant correlations of CREB1 with tumor stage and grade, vascular invasion (V1) and lymphovascular invasion (L1) were found. In this respect, ccRCC might differ from other solid tumors like esophageal squamous-cell carcinoma or glioma.

Citing Articles

Renal cancer: signaling pathways and advances in targeted therapies.

Jiang A, Li J, He Z, Liu Y, Qiao K, Fang Y MedComm (2020). 2024; 5(8):e676.

PMID: 39092291 PMC: 11292401. DOI: 10.1002/mco2.676.


Prognostic Value of Tumor Tissue Up-regulated microRNAs in Clear Cell Renal Cell Carcinoma (ccRCC).

Pesta M, Travnicek I, Kulda V, Ostasov P, Windrichova J, Houfkova K In Vivo. 2024; 38(4):1799-1805.

PMID: 38936941 PMC: 11215600. DOI: 10.21873/invivo.13631.


[MiR-26-3p regulates proliferation, migration, invasion and apoptosis of glioma cells by targeting CREB1].

Huang Q, Zhou J, Wang Z, Yang K, Chen Z Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(3):578-584.

PMID: 38597450 PMC: 11006701. DOI: 10.12122/j.issn.1673-4254.2024.03.20.


The emerging role of microRNA-22 in the Leukemia: experimental and clinical implications.

Xia J, Bu C, Zhang B, Wang X, Chen Y, Li T Mol Biol Rep. 2023; 51(1):12.

PMID: 38085373 DOI: 10.1007/s11033-023-08922-3.


Molecular insight into renal cancer and latest therapeutic approaches to tackle it: an updated review.

Murali R, Gopalakrishnan A Med Oncol. 2023; 40(12):355.

PMID: 37955787 DOI: 10.1007/s12032-023-02225-0.


References
1.
Muglia V, Prando A . Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras. 2015; 48(3):166-74. PMC: 4492569. DOI: 10.1590/0100-3984.2013.1927. View

2.
Humphrey P, Moch H, Cubilla A, Ulbright T, Reuter V . The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016; 70(1):106-119. DOI: 10.1016/j.eururo.2016.02.028. View

3.
Chow W, Dong L, Devesa S . Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010; 7(5):245-57. PMC: 3012455. DOI: 10.1038/nrurol.2010.46. View

4.
Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

5.
Capitanio U, Montorsi F . Renal cancer. Lancet. 2015; 387(10021):894-906. DOI: 10.1016/S0140-6736(15)00046-X. View